Amine-containing transfection reagents and methods for making and using same

Patent metadata

Field	Value
Publication number	US-11464863-B2
Application number	US-201916557967-A
Country	US
Kind code	B2
Filing date	Aug 30, 2019
Priority date	Nov 15, 2010
Publication date	Oct 11, 2022
Grant date	Oct 11, 2022

Abstract

There are provided for herein novel amine-containing transfection compounds and methods for making and using same. The compounds are generally obtained by reacting a primary amine with an unsaturated compound. Transfection complexes made using the amine-containing transfection compounds in combination with additional compounds to encapsulate biologically active agents such as nucleic acids are also provided for herein. Methods of using the transfection complexes for the in vivo or in vitro delivery of biologically active agents are also described. The transfection complexes of the present invention are highly potent, thereby allowing effective modulation of a biological activity at relatively low doses compared to analogous transfection compounds known in the art.

First claim

What is claimed is:

1. A transfection complex comprising:
an amine-containing transfection compound having the structure II, or pharmaceutically acceptable salts thereof

wherein:
each X 1 is independently selected from 0 or NH;
R 1 , is selected from substituted or unsubstituted, branched or unbranched alkyl or alkenyl groups having between 3 and about 20 carbon atoms and between 0 and about 4 double bonds;
R 2 , is selected from H or substituted or unsubstituted, branched or unbranched alkyl or alkenyl groups having between 3 and about 20 carbon atoms and between 0 and about 4 double bonds;
p is 0 or 1, and when n=p=0, R 2 is H,
n is 0, 1, 2, or 3;
m is 1, 2, or 3;
R 3 is selected from

wherein “HCC” symbolizes a straight or branched alkyl, alkenyl or alkynyl hydrocarbon chain having up to about 20 carbon atoms;
wherein one or each N* of R 3 indicates the nitrogen atom in structure II; and
wherein each g, e and f is independently an integer between 1 and 6;

at least one helper lipid; and
at least one bioactive agent selected from a DNA molecule, an RNA molecule, or a protein.

2. The transfection complex of claim 1 , further comprising a targeting moiety.

3. The transfection complex of claim 2 , wherein the targeting moiety selected from the group consisting of a peptide, an antibody, a receptor molecule, nucleic acid molecule, an aptamer, an organic molecule, and a polysaccharide.

4. The transfection complex of claim 3 , wherein the targeting moiety is a nuclear targeting moiety.

5. The transfection complex of claim 4 , wherein the nuclear targeting moiety is a peptide comprising one or more nuclear localization sequences.

6. The transfection complex of claim 1 , further comprising one or more fusogenic peptides.

7. The transfection complex of claim 1 , wherein the bioactive agent is an RNA molecule selected from siRNA, shRNA, miRNA, stRNA, and mRNA.

8. The transfection complex of claim 1 , further comprising at least one pegylated lipid.

9. The transfection complex of claim 1 , wherein e is 4.

10. The transfection complex of claim 1 , wherein f and g are 1.

11. The transfection complex of claim 1 , wherein n and m are 1 or 3.

12. The transfection complex of claim 1 , wherein e is 4, f and g are 1, and n and m are 1, 2, or 3.

13. The transfection complex of claim 1 , wherein the amine-containing transfection compound is selected from the group consisting of compounds 20, 22, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 48, 49, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 72, 73, 76, 77, 80, 81, 82, 83, 84, 85, and 86, or isomers thereof:

14. The transfection complex of claim 13 , further comprising a targeting moiety.

15. The transfection complex of claim 13 , further comprising one or more fusogenic peptides.

16. The transfection complex of claim 13 , further comprising at least one pegylated lipid.

17. The transfection complex of claim 16 , wherein the pegylated lipid is from about 0.5 to about 15 molar percentage of the complex.

18. The transfection complex of claim 13 , wherein the amine-containing compound is from about 15 to about 50 molar percentage of the complex.

19. The transfection complex of claim 1 , wherein the amine-containing compound is from about 15 to about 50 molar percentage of the complex.

20. The transfection complex of claim 8 , wherein the pegylated lipid is from about 0.5 to about 15 molar percentage of the complex.

21. The transfection complex of claim 1 , wherein the at least one helper lipid is selected from the group consisting of 3βOH-sterols; phosphatidylcholines; phosphatidylethanolamines; lecithins; glycerol esters; sphingolipids; cerebrosides; fatty acid esters; piperazine-based cationic lipids; phosphatidylserines; phosphatidylglycerols; diphosphatidylglycerols; diquaternary ammonium salts; N,N′-dicetyl saturated analogues; Ethyl-PC; ceramides, and derivatives thereof.

22. The transfection complex of claim 1 , wherein the at least one helper lipid is selected from the group consisting of cholesterol; DOPE (dioleoylphosphatidylethanolamine); and DOPC (dioleoylphosphatidylcholine), or salts thereof.

23. The transfection complex of claim 1 , wherein the at least one helper lipid is selected from the group consisting of BMOP (N-(2-bromoethyl)-N,N-dimethyl-2,3-bis(9-octadecenyloxy)-propanaminimium bromide); DDPES (Dipalmitoylphosphatidylethanolamine 5-carboxyspermylamide); DSPC; CTAB:DOPE (cetyltrimethylammonium bromide (CATB) and DOPE); POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine); DMG; DMAP (4-dimethylaminopyridine); DMPE (Dimyristoylphospatidylethanolamine); DOMG; DMA; DMPC (dimyristoylphosphatidylcholine); DPEPC (Dipalmitoylethylphosphatidylcholine); DODAC (dioleoydimethylammonium chloride); DOSPER (1,3-Di-Oleoyloxy-2-(6-Carboxyspermyl)-Propylamid); DOTMA (N-[1-(2,3-dioleyloxy)propyl]-n,n,n-trimethylammoniumchloride); DDAB (didoceyl methylammonium bromide); DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethyl-ammonium methylsulfate); DOTAP:Cl; DC-chol (3, β-N,(N′,N′-dimethylaminoethane)-carbamoyl]cholesterol); DC-6-14 (O,O′-Ditetradecanoyl-N-(alphatrimethylammonioacetyl) diethanolamine chloride); DCPE (Dicaproylphosphtidylethanolamine); DLRIE (dilauryl oxypropyl-3-dimethylhydroxy ethylammonium bromide); DODAP (1,2-Dioleoyl-3-dimethylammonium-propane); DOSPA (2,3-dioleoyloxy-N-[2-(sperminecarboxamidoethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate); DOGS (diocta

Assignees

• Life Technologies Corp

Inventors

• Yang Zhiwei
• Angrish Parul
• De Mollerat Du Jeu Xavier
• Wiederholt Kristin

Classifications

• C12N2310/141

  MicroRNAs, miRNAs · CPC title

• A61K47/543

  Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine · CPC title

• C07D211/28

  to which a second hetero atom is attached · CPC title

• A61K47/54 Primary

  the modifying agent being an organic compound · CPC title

• C12N15/88

  using microencapsulation, e.g. using {amphiphile} liposome vesicle · CPC title